STOCK TITAN

Astria Therapeutics Inc - ATXS STOCK NEWS

Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.

Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.

Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.

Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.

Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.

Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ: ATXS) has granted 130,000 stock options to two newly-hired employees as part of its 2022 Inducement Stock Incentive Plan. The awards, effective August 1, 2022, include a significant 100,000 options awarded to Dr. Chris Morabito, the new Chief Medical Officer, who joined the company on July 14, 2022. Each option has an exercise price of $3.87 per share and will vest over four years, contingent upon continued employment. These grants align with Nasdaq Listing Rule 5635(c)(4) regarding inducement awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ: ATXS) has received FDA clearance for its Investigational New Drug (IND) application for STAR-0215, a treatment for hereditary angioedema (HAE). A Phase 1a trial in healthy volunteers will start soon, with preliminary results expected by year-end. The company aims to provide effective, long-acting treatment with dosing every three months or longer. This IND acceptance marks a significant step toward clinical trials for STAR-0215, showcasing the company’s commitment to addressing unmet needs in rare allergic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.56%
Tags
none
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ: ATXS) has appointed Dr. Chris Morabito as Chief Medical Officer. Dr. Morabito, with over 20 years of experience in clinical development for rare diseases, is expected to lead clinical strategy as Astria prepares to transition into a clinical-stage company. The company aims to initiate its first-in-human trial for STAR-0215, a treatment for hereditary angioedema, later this year. Dr. Morabito previously served as CMO at Fulcrum Therapeutics and has held positions at major pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
none
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced its CEO, Jill C. Milne, will engage in a virtual fireside chat at the 1st Annual Hereditary Angioedema Conference on July 20 at 12:30 PM ET. The conference focuses on hereditary angioedema, a rare condition for which Astria is developing STAR-0215, a monoclonal antibody aimed at treating this disease. A live webcast will be available at this link, and an archived replay will be accessible on Astria's website for 30 days afterwards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
conferences
-
Rhea-AI Summary

Astria Therapeutics (NASDAQ: ATXS) presented new preclinical data showing that STAR-0215 effectively inhibits plasma kallikrein in cynomolgus monkeys, supporting potential dosing once every three months. This was discussed at the European Academy of Allergy and Immunology 2022 Congress in Prague. The study demonstrated rapid inhibition and prolonged pharmacological activity, with expectations to begin a Phase 1a clinical trial in healthy volunteers this year. The goal is to develop a patient-friendly treatment for hereditary angioedema (HAE).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced new preclinical data for STAR-0215, a treatment for hereditary angioedema (HAE), to be presented at the EAACI 2022 Hybrid Congress from July 1-3 in Prague. Pradeep Bista, VP of Discovery and Translational Sciences, will present findings on July 3 at 11:15 am CEST. STAR-0215 is designed for long-acting attack prevention, with dosing every three months or longer. The company plans to file an Investigational New Drug Application mid-year and initiate a Phase 1a trial with results expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
conferences
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) will present an overview of its lead program, STAR-0215, at the Jefferies Healthcare Conference on June 10 at 10:30 AM ET in New York. STAR-0215 is a monoclonal antibody aimed at treating hereditary angioedema, a rare immunological condition. The presentation will be led by CEO Jill C. Milne, Ph.D., and a webcast link is provided for access. An archived replay will be available on the company’s investor website for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) granted stock options for 5,500 shares as part of its 2022 Inducement Stock Incentive Plan on June 1, 2022. The options, aimed at new employees, have an exercise price of $3.12, equal to the stock's closing price on the grant date. Vesting occurs over four years, with 25% vesting on the first anniversary of each employee's start date and the rest monthly thereafter. This incentive plan conforms to Nasdaq Listing Rule 5635(c)(4) and is intended to attract talent in the biopharmaceutical sector focused on rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.05%
Tags
none
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced its quarterly financial results for Q1 2022 and shared updates on the STAR-0215 program for hereditary angioedema (HAE). The company plans to file an Investigational New Drug (IND) application mid-year 2022, aiming to begin a Phase 1a clinical trial shortly afterward, with initial results anticipated by year-end. Financially, Astria reported a net loss of $15.3 million, a significant improvement from $170.1 million in the same quarter last year. They maintain a cash position of $112.8 million to support operations into 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
Rhea-AI Summary

Astria Therapeutics (NASDAQ: ATXS) has announced it will present new preclinical data on its drug STAR-0215, aimed at treating hereditary angioedema (HAE), at the Fc Receptor and IgG Targeted Therapies Conference in Boston, Massachusetts, from April 26-28, 2022. Jou-Ku Chung, the Head of Clinical Pharmacology, will present on April 27 at 3:00 PM ET. STAR-0215 is designed as a long-acting monoclonal antibody with the potential for quarterly dosing, with plans to file an Investigational New Drug application mid-2022 and commence a Phase 1a trial thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
conferences
Astria Therapeutics Inc

Nasdaq:ATXS

ATXS Rankings

ATXS Stock Data

231.94M
49.58M
0.47%
104.71%
5.64%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON